Indapta Therapeutics Inc., 2025-10-14
An SEC Form D private-offering notice from Houston, TX, a $51,574,072 filer-stated offering target in Biotech. Filed 2025-10-14. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Develops an off the shelf, allogeneic g-NK natural killer cell therapy platform for cancer and autoimmune diseases, with lead candidate IDP-023 in Phase 1 trials for lymphoma, multiple myeloma and progressive multiple sclerosis.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Defiant Engineering, LLC, 2025-10-15, $1.9M, Montgomery, TX
- Belhaven Biopharma Inc., 2025-10-15, $32.3M, Chapel Hill, NC
- Krista Software Inc., 2025-10-15, $7.2M, Dallas, TX
- APPLIED DNA SCIENCES INC, 2025-10-15, $58M, Stony Brook, NY
- Polygraf Inc., 2025-10-14, $9.5M, Georgetown, TX
- Arkea Bio Corp., 2025-10-14, $12M, Charlestown, MA
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.